Bridger Management sold 47,841 shares of Masimo in the fourth quarter. The move resulted in the quarter-end position value decreasing by $7.06 million. The position was previously 3.8% of fund AUM as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A US appeals court has found in favor of Masimo in its fight against Apple over pulse oximetry patents, but in the court that matters, a ruling makes it clear that there won't be another ban on the ...

Apple's current blood oxygen sensing implementation in the U.S. does not infringe on patents owned by Masimo and Apple will not face a revived import ban, a U.S. International Trade Commission judge ...

There are two new developments in Apple’s ongoing legal battle with health technology company Masimo over the Apple Watch’s blood oxygen feature. First, an ITC Administrative Law Judge Monica ...

Fintel reports that on March 27, 2026, Raymond James downgraded their outlook for Masimo (NasdaqGS:MASI) from Outperform to Market Perform. Analyst Price Forecast Suggests 1.78% Upside As of March 27, ...

NYSE: BSX: $47.73 million (4.5% of AUM) NASDAQ: PODD: $40.04 million (3.8% of AUM) NASDAQ: DXCM: $38.99 million (3.7% of AUM) NYSE: SYK: $37.07 million (3.5% of AUM) NYSE: CVS: $35.73 million (3.4% of ...

Apple’s long-running legal dispute with Masimo over the blood oxygen feature in its smartwatches has taken another turn, following a new ruling from a US trade judge. Masimo previously secured a ...